The initiation of late-stage trials for the COVID-19-flu combination and standalone flu vaccines is a significant step for Novavax. Collaborating with the FDA for accelerated approval could expedite the process, potentially leading to earlier market entry and revenue generation. This development is likely to positively impact NVAX's stock price in the short term.